Aethlon Medical (NASDAQ: AEMD) director forfeits 178 shares for tax withholding

Q: What did Aethlon Medical (AEMD) director Nicolas Gikakis report in this Form 4?

The Form 4 reports that director Nicolas Gikakis forfeited 178 shares of Aethlon Medical common stock to cover tax withholdings arising from the conversion of vested restricted stock units into common shares.

Q: Was the AEMD Form 4 transaction an open-market sale of shares?

No. The Form 4 describes a tax-withholding disposition , not an open-market sale. 178 shares were forfeited to satisfy tax obligations when 268 restricted stock units converted into common shares.

Q: How many Aethlon Medical shares were forfeited for taxes in this filing?

Director Nicolas Gikakis forfeited 178 shares of Aethlon Medical common stock. The forfeiture price used was $2.19 per share , reflecting the market price at the time the tax-withholding transaction occurred.

Q: What equity award triggered the tax-withholding disposition for Aethlon Medical director Gikakis?

The disposition was triggered when 268 vested restricted stock units converted into Aethlon Medical common shares. To cover related tax withholdings, 178 of those resulting shares were forfeited at a market price of $2.19 per share .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Aethlon Medical director Nicolas Gikakis reported a tax-related share forfeiture. On the conversion of 268 vested restricted stock units into common stock, he forfeited 178 shares to cover tax withholdings, using a market price of $2.19 per share. Following the disposition, he holds 1,464 common shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gikakis Nicolas

Role Director

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	178	$2.19	$389.82

Holdings After Transaction: Common Stock — 1,464 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Shares forfeited for taxes: 178 shares Market price used: $2.19 per share RSUs converted: 268 units +2 more

5 metrics

Shares forfeited for taxes 178 shares Tax-withholding disposition on RSU conversion

Market price used $2.19 per share Price applied to forfeited shares for tax purposes

RSUs converted 268 units Vested restricted stock units converted to common stock

Shares held after transaction 1,464 shares Director’s direct common stock holdings post-disposition

Transaction date 2026-03-31 Date of tax-withholding disposition

Key Terms

restricted stock units, tax withholdings, forfeited, Form 4

4 terms

restricted stock units financial

"upon conversion of an aggregate 268 vested and outstanding restricted stock units into shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholdings financial

"to cover tax withholdings, using the market price of the issuer's common stock"

forfeited financial

"The Reporting Person forfeited 178 shares of common stock upon conversion"

Form 4 regulatory

"part of the grant reported in Table I of the Form 4 filed by the Reporting Person"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

04/01/2026 - 07:27 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gikakis Nicolas

(Last)

(First)

(Middle)

11555 SORRENTO VALLEY ROAD, SUITE 203

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AETHLON MEDICAL INC [ AEMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/31/2026		F		178⁽¹⁾	D	$2.19	1,464	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Reporting Person forfeited 178 shares of common stock upon conversion of an aggregate 268 vested and outstanding restricted stock units into shares of common stock to cover tax withholdings, using the market price of the issuer's common stock at the time of forfeiture. These restricted stock units were part of the grant reported in Table I of the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on April 25, 2025.

	/s/ Nicolas Gikakis, by: James B. Frakes, Attorney-in-fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Aethlon Medical (AEMD) director Nicolas Gikakis report in this Form 4?

The Form 4 reports that director Nicolas Gikakis forfeited 178 shares of Aethlon Medical common stock to cover tax withholdings arising from the conversion of vested restricted stock units into common shares.

Was the AEMD Form 4 transaction an open-market sale of shares?

No. The Form 4 describes a tax-withholding disposition, not an open-market sale. 178 shares were forfeited to satisfy tax obligations when 268 restricted stock units converted into common shares.

How many Aethlon Medical shares were forfeited for taxes in this filing?

Director Nicolas Gikakis forfeited 178 shares of Aethlon Medical common stock. The forfeiture price used was $2.19 per share, reflecting the market price at the time the tax-withholding transaction occurred.

How many Aethlon Medical (AEMD) shares does Nicolas Gikakis hold after the Form 4 transaction?

After the tax-withholding disposition, Nicolas Gikakis directly holds 1,464 shares of Aethlon Medical common stock. This figure reflects his direct ownership following forfeiture of 178 shares to satisfy tax obligations.

What equity award triggered the tax-withholding disposition for Aethlon Medical director Gikakis?

The disposition was triggered when 268 vested restricted stock units converted into Aethlon Medical common shares. To cover related tax withholdings, 178 of those resulting shares were forfeited at a market price of $2.19 per share.